Protagonist Retained Earnings from 2010 to 2024

PTGX Stock

USD 45.53 0.93 2.00%

Protagonist Therapeutics Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Protagonist Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2014-12-31

Previous Quarter

-439 M

Current Value

-472.2 M

Quarterly Volatility

192.9 M

Yuan Drop

Covid

Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 4.1 M or Selling General Administrative of 18 M, as well as many indicators such as Price To Sales Ratio of 20.61, Dividend Yield of 0.0 or PTB Ratio of 4.06. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.

Check out the analysis of Protagonist Therapeutics Correlation against competitors.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Latest Protagonist Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Protagonist Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Protagonist Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (615.71 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Protagonist Retained Earnings Regression Statistics

	Arithmetic Mean	(203,003,100)
	Coefficient Of Variation	(111.90)
	Mean Deviation	190,693,987
	Median	(101,550,000)
	Standard Deviation	227,163,806
	Sample Variance	51603.4T
	Range	603.2M
	R-Value	(0.92)
	Mean Square Error	8399.9T
	R-Squared	0.85
	Slope	(46,799,316)
	Total Sum of Squares	722447.5T

Protagonist Retained Earnings History

	2024	-584.9 M
	2023	-615.7 M
	2022	-536.8 M
	2021	-409.4 M
	2020	-283.8 M
	2019	-217.7 M
	2018	-140.5 M

Other Fundumenentals of Protagonist Therapeutics

Retained Earnings Total Equity

Protagonist Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Long Term Debt Total	Capital Surpluse	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Short Term Debt
Total Assets		-0.25	0.99	-0.87	-0.85	0.39	0.5	0.96	0.3	-0.8	1.0	0.1	0.51	0.78	0.84	0.91	-0.77	0.87	0.9	0.75
Total Stockholder Equity	-0.25		-0.35	-0.09	0.0	-0.57	0.53	-0.32	-0.59	0.22	-0.24	-0.01	-0.34	-0.11	-0.33	-0.05	0.06	-0.01	-0.03	-0.46
Net Tangible Assets	0.99	-0.35		-0.84	-0.81	0.44	0.39	0.96	0.34	-0.77	0.98	0.03	0.46	0.74	0.84	0.88	-0.78	0.85	0.88	0.79
Net Debt	-0.87	-0.09	-0.84		0.91	-0.26	-0.66	-0.74	-0.28	0.71	-0.87	-0.19	-0.23	-0.73	-0.69	-0.93	0.88	-0.82	-0.83	-0.68
Retained Earnings	-0.85	0.0	-0.81	0.91		-0.25	-0.64	-0.8	-0.45	0.84	-0.86	-0.17	-0.43	-0.85	-0.65	-0.99	0.86	-0.82	-0.86	-0.81
Accounts Payable	0.39	-0.57	0.44	-0.26	-0.25		0.17	0.37	0.42	-0.62	0.39	0.08	0.23	0.54	0.6	0.29	-0.37	0.06	0.11	0.29
Net Receivables	0.5	0.53	0.39	-0.66	-0.64	0.17		0.42	-0.19	-0.62	0.5	0.07	0.34	0.65	0.52	0.63	-0.45	0.38	0.44	0.1
Short Term Investments	0.96	-0.32	0.96	-0.74	-0.8	0.37	0.42		0.24	-0.8	0.96	0.05	0.62	0.78	0.78	0.86	-0.69	0.85	0.89	0.76
Total Liab	0.3	-0.59	0.34	-0.28	-0.45	0.42	-0.19	0.24		-0.37	0.29	0.09	0.06	0.31	0.3	0.4	-0.4	0.19	0.2	0.67
Long Term Investments	-0.8	0.22	-0.77	0.71	0.84	-0.62	-0.62	-0.8	-0.37		-0.8	-0.24	-0.62	-0.98	-0.69	-0.84	0.76	-0.63	-0.7	-0.69
Total Current Assets	1.0	-0.24	0.98	-0.87	-0.86	0.39	0.5	0.96	0.29	-0.8		0.12	0.5	0.79	0.83	0.91	-0.78	0.88	0.91	0.75
Common Stock	0.1	-0.01	0.03	-0.19	-0.17	0.08	0.07	0.05	0.09	-0.24	0.12		0.15	0.35	-0.22	0.13	-0.19	0.17	0.18	0.18
Property Plant Equipment	0.51	-0.34	0.46	-0.23	-0.43	0.23	0.34	0.62	0.06	-0.62	0.5	0.15		0.57	0.47	0.44	-0.16	0.28	0.36	0.41
Long Term Debt	0.78	-0.11	0.74	-0.73	-0.85	0.54	0.65	0.78	0.31	-0.98	0.79	0.35	0.57		0.6	0.85	-0.78	0.68	0.74	0.67
Long Term Debt Total	0.84	-0.33	0.84	-0.69	-0.65	0.6	0.52	0.78	0.3	-0.69	0.83	-0.22	0.47	0.6		0.7	-0.53	0.51	0.56	0.48
Capital Surpluse	0.91	-0.05	0.88	-0.93	-0.99	0.29	0.63	0.86	0.4	-0.84	0.91	0.13	0.44	0.85	0.7		-0.88	0.85	0.88	0.82
Current Deferred Revenue	-0.77	0.06	-0.78	0.88	0.86	-0.37	-0.45	-0.69	-0.4	0.76	-0.78	-0.19	-0.16	-0.78	-0.53	-0.88		-0.82	-0.82	-0.8
Net Invested Capital	0.87	-0.01	0.85	-0.82	-0.82	0.06	0.38	0.85	0.19	-0.63	0.88	0.17	0.28	0.68	0.51	0.85	-0.82		0.99	0.75
Net Working Capital	0.9	-0.03	0.88	-0.83	-0.86	0.11	0.44	0.89	0.2	-0.7	0.91	0.18	0.36	0.74	0.56	0.88	-0.82	0.99		0.76
Short Term Debt	0.75	-0.46	0.79	-0.68	-0.81	0.29	0.1	0.76	0.67	-0.69	0.75	0.18	0.41	0.67	0.48	0.82	-0.8	0.75	0.76

Click cells to compare fundamentals

About Protagonist Therapeutics Financial Statements

Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-615.7 M	-584.9 M
Retained Earnings Total Equity	-483.1 M	-458.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC